From the Laboratory to the Clinic: Anti-TNF and Anti-IL-23 Combination Therapy in Inflammatory Bowel Disease

Learning Objectives:

• Upon completion, participant will be able to describe the in silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in inflammatory bowel disease.
• Upon completion, participant will be able to describe the rationale for use of anti-TNF and anti-IL-23 as a combination treatment for patients with inflammatory bowel disease.
• Upon completion, participant will be able to describe the efficacy and safety of combination induction therapy with Guselkumab and Golimumab at week 12 of a Ph2a randomized, double-blind, active-controlled, proof-of-concept study in participants with moderately-to-severely active ulcerative colitis.